however, dedicated trials targeting high-risk CMS populations including those with obesity, insulin resistance, and early-stage hypertension are still necessary.38, 41, 42, 43, 64 Such studies should explore optimal patient selection, treatment duration, and potential synergistic effects when combined with other metabolic and cardiovascular therapies
All eight reported studies have demonstrated the noninferiority of GLP-1RAs compared to placebo regarding MACE
Weight gain following major life transitions like international relocation is incredibly common and presents unique challenges: For those experiencing post-relocation weight gain, a combination of adaptive strategies may be more effective than medication: Before pursuing GLP-1 medications, understanding the potential for weight regain is crucial
Is Ozempic the answer for weight loss